RG
MDNA

Rathbones Group’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Rathbones Group’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-105,663
Closed -$33.8K – 648
2023
Q4 		$33.8K Hold
105,663
– – ﹤0.01% 593
2023
Q3 		$31.7K Hold
105,663
– – ﹤0.01% 607
2023
Q2 		$50.7K Hold
105,663
– – ﹤0.01% 402
2023
Q1 		$68.7K Hold
105,663
– – ﹤0.01% 399
2022
Q4 		$49.7K Hold
105,663
– – ﹤0.01% 414
2022
Q3 		$87K Buy
105,663
+65,663
+164% +$74.1K ﹤0.01% 397
2022
Q2 		$46K Hold
40,000
– – ﹤0.01% 420
2022
Q1 		$53K Hold
40,000
– – ﹤0.01% 418
2021
Q4 		$66K Hold
40,000
– – ﹤0.01% 416
2021
Q3 		$110K Hold
40,000
– – ﹤0.01% 407
2021
Q2 		$121K Hold
40,000
– – ﹤0.01% 410
2021
Q1 		$163K Hold
40,000
– – ﹤0.01% 384
2020
Q4 		$187K Hold
40,000
– – ﹤0.01% 367
2020
Q3 		$164K Buy
+40,000
New +$161K ﹤0.01% 352

Rathbones Group's MDNA Position: Q1 2024 in Review

Rathbones Group sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q1 2024, closing a stake of 105,663 shares — an estimated $33.8K sold.

Rathbones Group first reported a position in MDNA in Q3 2020 and held it in 14 quarters. The position peaked at $187K in Q4 2020. 0 funds tracked by Wall St. Rank hold MDNA as of Q1 2024.

  • Rathbones Group reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q1 2024 after selling out during the quarter.
  • Rathbones Group sold 105,663 Medicenna Therapeutics Corp. Common Shares shares in Q1 2024, an estimated $33.8K.
  • Rathbones Group first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2020 and held it in 14 quarters.
  • Rathbones Group's Medicenna Therapeutics Corp. Common Shares position peaked at $187K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q1 2024.

Based on Rathbones Group's 13F filing for Q1 2024, filed 14 May 2024.